These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 20467269)

  • 1. Sex differences in effects of valsartan administration on cardiovascular outcomes in hypertensive patients: findings from the Jikei Heart Study.
    Yoshida H; Shimizu M; Ikewaki K; Taniguchi I; Tada N; Yoshimura M; Rosano G; Dahlöf B; Mochizuki S;
    J Hypertens; 2010 Jun; 28(6):1150-7. PubMed ID: 20467269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: An analysis of findings from the VALUE trial.
    Zanchetti A; Julius S; Kjeldsen S; McInnes GT; Hua T; Weber M; Laragh JH; Plat F; Battegay E; Calvo-Vargas C; Cieśliński A; Degaute JP; Holwerda NJ; Kobalava J; Pedersen OL; Rudyatmoko FP; Siamopoulos KC; Störset O
    J Hypertens; 2006 Nov; 24(11):2163-8. PubMed ID: 17053536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
    Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
    Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardio-cerebrovascular protective effects of valsartan in high-risk hypertensive patients with coronary artery disease (from the Kyoto Heart Study).
    Shiraishi J; Sawada T; Koide M; Yamada H; Matsubara H;
    Am J Cardiol; 2012 May; 109(9):1308-14. PubMed ID: 22325086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. JIKEI HEART Study--a morbi-mortality and remodeling study with valsartan in Japanese patients with hypertension and cardiovascular disease.
    Mochizuki S; Shimizu M; Taniguchi I; Kanae K; Yoshida S; Tajima N; Dahlöf B;
    Cardiovasc Drugs Ther; 2004 Jul; 18(4):305-9. PubMed ID: 15367828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-group trial.
    Lacourcière Y; Poirier L; Hebert D; Assouline L; Stolt P; Rehel B; Khder Y
    Clin Ther; 2005 Jul; 27(7):1013-21. PubMed ID: 16154480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of valsartan versus amlodipine in diabetic hypertensive patients with or without previous cardiovascular disease.
    Yamashita K; Kondo T; Muramatsu T; Matsushita K; Nagahiro T; Maeda K; Shintani S; Murohara T
    Am J Cardiol; 2013 Dec; 112(11):1750-6. PubMed ID: 24035165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy.
    Julius S; Weber MA; Kjeldsen SE; McInnes GT; Zanchetti A; Brunner HR; Laragh J; Schork MA; Hua TA; Amerena J; Balazovjech I; Cassel G; Herczeg B; Koylan N; Magometschnigg D; Majahalme S; Martinez F; Oigman W; Seabra Gomes R; Zhu JR
    Hypertension; 2006 Sep; 48(3):385-91. PubMed ID: 16864741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of baseline and changes in systolic blood pressure over time on the effectiveness of valsartan in the Valsartan Heart Failure Trial.
    Anand IS; Rector TS; Kuskowski M; Thomas S; Holwerda NJ; Cohn JN
    Circ Heart Fail; 2008 May; 1(1):34-42. PubMed ID: 19808268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study.
    Mochizuki S; Dahlöf B; Shimizu M; Ikewaki K; Yoshikawa M; Taniguchi I; Ohta M; Yamada T; Ogawa K; Kanae K; Kawai M; Seki S; Okazaki F; Taniguchi M; Yoshida S; Tajima N;
    Lancet; 2007 Apr; 369(9571):1431-1439. PubMed ID: 17467513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modelling of blood pressure and total cardiovascular risk outcomes after second-line valsartan therapy: the BSCORE study.
    Lins R; Coen N; Aerts A; Macdonald K; Brié H; Hermans C; Shen YM; Lee C; Vancayzeele S; Mecum N; Abraham I
    Arch Cardiovasc Dis; 2011 Aug; 104(8-9):428-34. PubMed ID: 21944144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale and design of the KYOTO HEART study: effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high risk of cardiovascular events.
    Sawada T; Takahashi T; Yamada H; Dahlöf B; Matsubara H;
    J Hum Hypertens; 2009 Mar; 23(3):188-95. PubMed ID: 18800142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
    Anand IS; Bishu K; Rector TS; Ishani A; Kuskowski MA; Cohn JN
    Circulation; 2009 Oct; 120(16):1577-84. PubMed ID: 19805651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The VALUE trial: a commentary.
    Sever P
    J Renin Angiotensin Aldosterone Syst; 2004 Sep; 5(3):99-101. PubMed ID: 15526243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial.
    Schmieder RE; Kjeldsen SE; Julius S; McInnes GT; Zanchetti A; Hua TA;
    J Hypertens; 2008 Mar; 26(3):403-11. PubMed ID: 18300848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A drug safety evaluation of valsartan.
    Fogari R; Zoppi A
    Expert Opin Drug Saf; 2011 Mar; 10(2):295-303. PubMed ID: 21142805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A meta-analysis of randomized trials of telmisartan vs. valsartan therapy for blood pressure reduction.
    Takagi H; Niwa M; Mizuno Y; Goto SN; Umemoto T;
    Hypertens Res; 2013 Jul; 36(7):627-33. PubMed ID: 23344134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amlodipine/valsartan single-pill combination: a review of its use in the management of hypertension.
    Frampton JE; Scott LJ
    Am J Cardiovasc Drugs; 2009; 9(5):309-30. PubMed ID: 19791840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of supportive measures on drug adherence in patients with essential hypertension treated with valsartan: the randomized, open-label, parallel group study VALIDATE.
    Düsing R; Handrock R; Klebs S; Tousset E; Vrijens B
    J Hypertens; 2009 Apr; 27(4):894-901. PubMed ID: 19300114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ambulatory versus clinic blood pressure for the assessment of anti hypertensive efficacy in clinical trials: insights from the Val-Syst Study.
    Palatini P; Dorigatti F; Mugellini A; Spagnuolo V; Varì N; Ferrara R; Bertocchi F
    Clin Ther; 2004 Sep; 26(9):1436-45. PubMed ID: 15531006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.